A&C - Restraint on alienation of assets cannot be imposed when such relief was neither specifically sought nor argued in Section 17 application: HC (See 'Legal Desk') A&C - Scope of scrutiny u/s 11 is confined to prima facie examination of existence of arbitration agreement & does not extend to adjudication of disputed questions of fact or law: HC (See 'Legal Desk') Dasheri, Chausa, Langra and Kesar showcase Rich Diversity of Indian Mangoes (See 'Corp Brief') Ease of Doing Business: Irritants eased out of FSSAI Licensing Regulations (See 'Corp Brief') AI, Nuclear, Space, Quantum tech to determine contours of future growth: MoS (See 'Corp Brief') NBA releases SOP for Scientific Identification of Threatened Species by States and UTs (See 'Corp Brief') Over 1.31 Crore Citizens Join 'Nasha Mukt Bharat Saptah' 2026 (See 'Corp Brief') MSP Procurement extended till July 8; 6.18 Lakh PMAY-G houses cleared for UP (See 'Corp Brief') ICAR and APEDA Sea Protocol cuts Mango Export Cost (See 'Corp Brief') APEDA facilitates First Shipment of Premium Banganapalle Mangoes to Singapore (See 'Corp Brief') Cooperative banks must adopt modern tech platforms to remain relevant: Secy (See 'Corp Brief') APEDA facilitates First Biscuit Export Shipment from Varanasi to Oman (See 'Corp Brief') FEMA - Statutory protection under Section 6(4) cannot be invoked to legitimise unexplained or inadequately accounted foreign exchange transactions: SAFEMA (See 'Legal Desk') Vande Mataram Camp commences at Brainware University, West Bengal (See 'Corp Brief') Digitalization no longer a Choice, but Steel Sector's Survival Strategy: Kumaraswamy (See 'Corp Brief') IP 2026 establishes Standards for Blood and Blood Components (See 'Corp Brief') Ministry of Coal organises BRICS Side Event on Clean Coal Technologies (See 'Corp Brief') SEBI - Failure to file Quarterly Activity Reports for multiple consecutive quarters constitutes violation of regulatory framework & attracts consequences prescribed under Regulation 35 of AIF Regulations, 2012: SEBI (See 'Legal Desk') 100 Startups from 22 States complete Export-Focused Acceleration Programme (See 'Corp Brief') MoS pitches 'BRICS Space Economy' (See 'Corp Brief') IPC successfully conducts Training on Ethylene Glycol & DEG in Preparations by Gas Chromatography (See 'Corp Brief') Unlocking Potential of Idle Financial Assets in India (See 'Corp Brief') SARFAESI - In absence of any adjudication by the DRT in determining the debt, statutory scheme permits reliance upon claim made by secured creditor for purpose of fixing pre-deposit: HC (See 'Legal Desk') CCI okays acquisition of shares in Nxtra Data by Alpha Wave Ventures (See 'Corp Brief') CCI okays acquisition of 21% voting interest in Astemo Ltd. by Honda Motor (See 'Corp Brief') FEMA - Claims & liabilities pertaining to periods prior to approval of resolution plan, which do not survive under approved plan, are extinguished & cannot be enforced: SAFEMA (See 'Legal Desk') Special Drive launched for expeditious Disposal of Long-Pending Labour Cases (See 'Corp Brief') Amit Shah to launch NAFED's auction portal 'NAFEX.in' (See 'Corp Brief') SEBI - A judicial pronouncement cannot ordinarily be modified or reviewed through post-disposal miscellaneous application; Tribunal becomes functus officio upon disposal of appeal: SAT (See 'Legal Desk') Railways approves Kavach Deployment Worth Rs.270 Crore on East Coast (See 'Corp Brief') DIBD and AISF sign MoU to promote Language Technology and Multilingual Innovation in Assam (See 'Corp Brief') IPR - Injunction allowed as defendant's adoption of marks is not honest or bona fide; marks are deceptively similar to plaintiff's registered trademark, such that an average consumer with imperfect recollection would likely be confused: HC (See 'Legal Desk') NMDC accelerates Digitalisation and Sustainable Mining to support 100 MTPA Vision (See 'Corp Brief') Union Minister sanctions over 42,000 houses in MP; 38,000 families perform grih pravesh (See 'Corp Brief') A&C - Where a Section 34 court has already examined the award, a possible alternative interpretation of the contractual clause is insufficient to justify interference: HC (See 'Legal Desk') Tech Innovation and disruption in Construction Industry (See 'CORP EINSICHT') Union Minister reviews Power Sector and Urban Development Schemes with Jharkhand Govt (See 'Corp Brief') APEDA facilitates First Export of fresh Uttarakhand Litchi to Italy (See 'Corp Brief') Trade Marks - Quasi-judicial authority cannot validly base its decision on grounds that were not specifically disclosed in SCN, thereby depriving noticee of an effective opportunity to respond: HC (See 'Legal Desk') Nadda calls for Push towards a TB-Free India (See 'Corp Brief') India must take control of security-related necessities to remain future-ready: RM (See 'Corp Brief') A&C - Financial hardship cannot justify payment of disputed amount linked to fulfilment of deliverable-based obligations: HC (See 'Legal Desk')

Print

Govt hosts workshop on increasing R&D in pharma-medical tech sector

Published: Mar 13, 2025

By TIOLCorplaws News Service

NEW DELHI, MAR 13, 2025: THE Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, organised a workshop on the Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) Scheme today. The workshop was inaugurated in the presence of the Secretaries of five stakeholder Ministries and Departments of the Government of India, namely, Amit Agrawal, Secretary, Department of Pharmaceuticals; Prof. Abhay Karandikar, Secretary, Department of Science and Technology (DST); S. Krishnan, Secretary, Ministry of Electronics and Information Technology (MeitY); Dr N. Kalaiselvi, Secretary, Department of Scientific and Industrial Research (DSIR) and Director General (DG), Council of Scientific and Industrial Research (CSIR); and Dr Rajiv Bahl, Secretary, Department of Health Research (DHR) and DG, Indian Council for Medical Research (ICMR). The workshop served as a platform for identifying key action points and approaches to further the shared commitment to promote research and development in the pharmaceuticals and medical technologies sector.

Amit Agrawal, Secretary, Department of Pharmaceuticals highlighted the rapid expansion in the sector, underscoring the importance of research and innovation in driving making and innovating in India for India and the world. In this regard, he highlighted that the global share of personalised and precision technology platforms (such as antibody-drug conjugates, bi-specific antibodies, and cell and gene therapy) among the top-100 drugs by value is growing rapidly, from 5% in 2020 to 9% in 2025 and projected to grow to 20% by 2030. He also highlighted the 10 times increase in the number of Indian healthcare and life sciences startups over the last four years, from over 900 in 2020 to more than 10,000 in 2024, as well as the growing pipeline of innovative products of Indian firms.

Amit Agrawal said that the groundwork and the pipeline for projects for the PRIP scheme has been laid through this growing innovation ecosystem of Indian startups and industry, supported by a wide array of initiatives of the scientific Ministries/ Departments. The latter include the clinical trial network created by CSIR under its INTENT initiative; the patenting support available through DST's TIFAC and ICMR's Patent Mitra initiative; the handholding support available to both medical technology and drug innovations through ICMR's MedTech Mitra initiative; the funding support available to startups through Department of Biotechnology's BIRAC, MeitY's TIDE 2.0 and SAMRIDH schemes and DST's Quantum Computing Mission, etc.

Reiterating the Government's commitment to a robust research ecosystem, Amit said that PRIP is a transformative initiative aimed at catalysing innovation, strengthening industry-academia linkages, and positioning India as a global leader in pharmaceutical and MedTech research.

Prof. Abhay Karandikar, Secretary, DST underscored the importance of cutting-edge scientific research in driving advancements in pharmaceuticals and MedTech, reinforcing India's healthcare ecosystem and highlighted the supports available through the extensive incubator and accelerator network of DST.

S. Krishnan, Secretary, MeitY emphasised the transformative potential of digital health, artificial intelligence (AI) and data-driven technologies in drug discovery and medical device development. He highlighted the research strengths of MeitY's organisations, such as Society for Applied Microwave Electronics Engineering and Research (SAMEER), C-DAC and Centre for Materials for Electronics Technology (C-MET).

Dr Rajiv Bahl, Secretary, DHR and DG, ICMR highlighted the critical role of clinical research, indigenous drug development and regulatory advancements in accelerating pharmaceutical innovation. He offered the full support of the ICMR INTENT, MedTech Mitra and Patent Mitra initiatives in taking forward the shared goals of PRIP scheme. He also said that the industry-academia collaborative research window under the scheme could be of considerable help in taking forward the large volume of intramural and extramural research being funded by ICMR to the market with funding from PRIP and industry involvement.

Dr N. Kalaiselvi, Secretary, DSIR and DG, CSIR underscored the need to foster a culture of scientific collaboration between research institutions and industry to ensure the seamless translation of research into commercially viable applications. She highlighted that considerable research done in CSIR labs could be taken to the market through collaboration with industry and funding from PRIP.

The discussions reaffirmed the Government's vision of transforming India into a global hub for research and innovation in pharmaceuticals and medical technology. The workshop featured four dedicated breakout sessions, bringing together over 100 participants from leading scientific departments and premier institutions, including the National Institutes of Pharmaceutical Education and Research, IITs, CSIR labs and organisations of ICMR, MeitY, DST and Department of Bio technology, along with key government enablers for the ecosystem. Key deliberations covered the emerging trends in pharmaceutical and MedTech research, strategies for translating research into commercially viable products, government support mechanisms to accelerate sectoral growth and flexibilities sought to maximise the impact from the PRIP scheme.

All participants were requested to share their suggestions in the Expression of Interest (EoI) form for the PRIP scheme hosted on the website of the Department of Pharmaceuticals, so that these may be taken into account while taking forward the scheme and enabling participants. The EoI would be open till April 7, 2025.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.